key: cord-0019841-6nkcmrfj
authors: Soriano, Alex; Carmeli, Yehuda; Omrani, Ali S.; Moore, Luke S. P.; Tawadrous, Margaret; Irani, Paurus
title: Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
date: 2021-08-11
journal: Infect Dis Ther
DOI: 10.1007/s40121-021-00507-6
sha: 347da2c2f525c3219940dd825951a6dfcdd64a9e
doc_id: 19841
cord_uid: 6nkcmrfj

INTRODUCTION: A systematic literature review was undertaken to evaluate real-world use of ceftazidime-avibactam for infections due to aerobic Gram-negative organisms in adults with limited treatment options. METHODS: Literature searches retrieved peer-reviewed publications and abstracts from major international infectious disease congresses from January 2015 to February 2021. Results were screened using pre-defined criteria to limit the dataset to relevant publications (notable exclusions were paediatric data and outcomes data for bacteria intrinsically resistant to ceftazidime-avibactam). Data for included publications were subjected to qualitative synthesis. RESULTS: Seventy-three relevant publications (62 peer-reviewed articles; 10 abstracts) comprising 1926 patients treated with ceftazidime-avibactam (either alone or combined with other antimicrobials) and 1114 comparator/control patients were identified. All patients were hospitalised for serious illness and most had multiple comorbidities. The most common infections were pneumonia, bacteraemia, and skin/soft tissue, urinary tract, or abdominal infections; smaller numbers of patients with meningitis, febrile neutropenia, osteomyelitis, and cystic fibrosis were also included. Carbapenem-resistant or carbapenemase-producing Enterobacterales (CRE; n = 1718) and carbapenem-resistant, multidrug-resistant (MDR), and extensively drug-resistant Pseudomonas aeruginosa (n = 150) were the most common pathogens. Most publications reported positive outcomes for ceftazidime-avibactam treatment (clinical success rates ranged from 45 to 100% and reported 30-day mortality from 0 to 63%), which were statistically superior versus comparators in some studies. ceftazidime-avibactam resistance emergence occurred infrequently and mostly in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains. CONCLUSION: This review provides qualitative evidence of successful use of ceftazidime-avibactam for the treatment of hospitalised patients with CRE and MDR P. aeruginosa infections with limited treatment options. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00507-6.

Antimicrobial resistance among Gram-negative bacteria, including Acinetobacter species, Enterobacterales, and Pseudomonas aeruginosa, represents a significant problem for healthcare systems worldwide, in particular for resistance epicentres with high local prevalence of extended-spectrum b-lactamase (ESBL)-and carbapenemase-producing organisms, where treatment options for infections caused by such pathogens can be severely limited [1] . The need for antimicrobial development to address thirdgeneration cephalosporin-resistant and carbapenem-resistant Enterobacterales (CRE) and P. aeruginosa has been designated a critical priority by the World Health Organization [2] .

Ceftazidime-avibactam, a combination of the anti-pseudomonal cephalosporin ceftazidime and the novel b-lactamase inhibitor avibactam, has in vitro activity against a broad range of Gram-negative bacteria, including highly resistant strains, such as ESBL-, AmpC-, and serine carbapenemase-producing Enterobacterales (CPE) and P. aeruginosa, but not against metallo-b-lactamase (MBL) producers [3, 4] . In an extensive phase 2 and 3 randomised controlled trial (RCT) programme, ceftazidime-avibactam has demonstrated efficacy generally comparable to carbapenem-based comparator regimens in the primary indications of complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI; including pyelonephritis), and hospital-acquired pneumonia (HAP/HABP; including ventilator-associated pneumonia [VAP/VABP]) [5] [6] [7] [8] [9] [10] [11] , including against ceftazidime non-susceptible and multidrug-resistant (MDR) Enterobacterales and P. aeruginosa [6, 12] . Ceftazidime-avibactam (standard dose 2.5 g by 2-h intravenous infusions every 8 h [q8h], adjusted for patients with creatinine clearance [CrCL] C 50 ml/min) is approved in the US for the treatment of adults with cIAI (co-administered with metronidazole), cUTI (including pyelonephritis) and HABP (including VABP), and cIAI or cUTI (including pyelonephritis) in children aged C 3 months [13] . In Europe it is approved for cUTI (including pyelonephritis), cIAI, and HAP/VAP in adults, including for cases of bacteraemia associated with these infections, and for the treatment of infections due to aerobic Gram-negative organisms with limited treatment options [14] . It is also approved for children aged C 3 months with cUTI (including pyelonephritis), cIAI, HAP/VAP, and infections due to aerobic Gram-negative organisms with limited treatment options [14] . Approval of ceftazidime-avibactam for the 'limited treatment options' indication in adults was based on microbiological data, demonstration of clinical efficacy in patients with cIAI and cUTI, and population pharmacokinetic (PK) data demonstrating adequate PK/pharmacodynamic (PD) target attainment with approved dosages [15] . By definition, there is a lack of RCT data describing outcomes of treatment for this diverse patient population. However, there is a growing body of published (predominantly retrospective and observational) data on the use of ceftazidime-avibactam in indications for which there are limited treatment options. This systematic literature review provides a qualitative synthesis of the clinical and microbiological outcomes of ceftazidime-avibactam treatment of infections caused by aerobic Gramnegative organisms in adult patients with limited treatment options. This article is based on published literature and does not contain any previously unreported studies with human participants or animals.

For the purposes of this review, a working definition of publications describing 'aerobic Gramnegative infections in adult patients with limited treatment options' was formulated. Publications reporting outcomes for patients with any of the approved 'primary' indications for ceftazidime-avibactam (cIAI, cUTI, HAP/HABP, or VAP/VABP) were only included if the infection(s) involved microbiological confirmation/suspicion of ESBL-and/or carbapenemaseproducing Gram-negative organisms, excluding MBL producers. Other acute infections included in the working definition of 'limited treatment options' were those with microbiological confirmation/suspicion of involvement of ceftazidime-avibactam-susceptible Gram-negative bacteria (i.e., non-MBL-producing Enterobacterales or P. aeruginosa), such as primary or secondary bacteraemia/bloodstream infections including sepsis/toxic shock, bacterial meningitis, febrile neutropenia, device-related infections, transplant-related infections, bone and joint infections, cystic fibrosis-related bronchopulmonary infections, and skin and soft tissue infections (SSTI).

Methodology for conducting literature searches followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and guidance [16, 17] . A PubMed search using the search terms 'ceftazidime AND avibactam' (filters: none) was conducted in February 2021 to include publications from 2015 onwards. Additional searches were conducted to retrieve abstracts from major international infectious disease congresses All retrieved publication search results were screened by two researchers by titles and abstracts. The following publication types were excluded, with reasons for exclusion documented in each case: RCT data for any of the primary indications for ceftazidime-avibactam; in vitro/animal study data, including microbiological surveillance or population PK and PK/ PD modelling; review articles, guidelines, commentaries/opinion pieces, and editorials not reporting original outcomes data for patients treated with ceftazidime-avibactam; publications primarily reporting outcomes of treatment for infections caused by pathogens not susceptible to ceftazidime-avibactam as defined in the European Summary of Product Characteristics [i.e., Staphylococcus aureus (methicillin-resistant and methicillin-sensitive), anaerobes, Enterococcus spp., Stenotrophomonas maltophilia, and Acinetobacter spp.] [14] , or those describing outcomes of MBL-producing Gram-negative infections. Meta-analyses of published literature were also excluded from the analysis to avoid duplication of data; however, the source data/ references within such articles were reviewed to ensure all relevant primary data were included.

Included publications were tabulated in Microsoft Excel for data extraction. In addition to author/citation details, the following data (where reported) were extracted for each included publication: country/region; study design; number of sites (single or multiple); number of ceftazidime-avibactam and control/comparator participants and their characteristics [age, sex, type of infection, clinical isolate(s) and resistance mechanism(s), renal status, and intensive care unit (ICU) admittance]; primary/index infection and proportion of patients with bacteraemia; duration of ceftazidime-avibactam treatment and use of prior and concomitant antibiotics; timing relative to index infection and duration of ceftazidime-avibactam treatment; clinical and microbiological outcomes (for example, hospital, 30-day, or 90-day mortality), and rates of eradication, recurrence, and emergence of resistance.

The literature search identified a total of 1262 publications, from which initial screening and further exclusion identified 73 relevant publications (Fig. 1 

Data for 95 patients treated with ceftazidimeavibactam from two prospective studies were included [18, 19] . Both studies included patients with CRE infections; no decreased susceptibility/ceftazidime-avibactam resistance emergence was reported in either study. Sousa et al. (2018) prospectively collected data on outcomes of ceftazidime-avibactam salvage therapy for 57 patients with OXA-48producing K. pneumoniae infections during an outbreak caused by this pathogen at a Spanish hospital [18] . The most common primary infections were intra-abdominal [ 

Data for 481 patients treated with ceftazidimeavibactam from 12 retrospective comparative/case-control studies ( Table 2) were retrieved from the literature search [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Each of these studies involved infections caused by CRE and most of the patients were bacteraemic; some included patients treated on a 'compassionate use' basis before the commercial availability of ceftazidime-avibactam (the drug was first approved in the US in 2015). Comparator treatments comprised best available therapy (BAT) and included polymyxin B, colistin, aminoglycosides and tigecycline alone or in combination with carbapenems and unspecified 'salvage agents' (Table 2) . Clinical outcomes included clinical cure and 30-and 90-day mortality rates. Across these studies, efficacy outcomes for ceftazidime-avibactam (where reported) were in general numerically similar or superior to those reported for comparator treatments ( Table 2) . Emergence of resistance to ceftazidime-avibactam in three of eight patients with recurrent infections (38%) was reported in one congress abstract involving 35 solid organ transplant (SOT) patients with CRE infections (predominantly bacteraemia or pneumonia); however, the duration of ceftazidime-avibactam treatment, resistance mechanism(s), and timing of resistance emergence were not reported [29] . Of note, a non-comparative retrospective analysis by the same investigators (see below) reported an overall rate of ceftazidime-avibactam resistance emergence of 10% among 77 patients infected with CRE, of whom 4 were SOT recipients [32] . A separate study among 147 patients treated with KPC-or OXA-48-producing K. pneumoniae infections treated with ceftazidime-avibactam reported a lower rate of resistance emergence of 1% (2/ 147 patients); details of timings and mechanism(s) were not reported [25] .

Data for 1155 patients treated with ceftazidimeavibactam from 16 retrospective non-comparative cohort/chart review studies were identified (Table 3 ) [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] , the majority of which involved CRE/CPE infections (981 patients); six publications included data for P. aeruginosa infections (124 patients). Emergence of resistance and/or reduced susceptibility to ceftazidime-avibactam was reported in seven of these publications, including one OXA-48-producing K. pneumoniae in a single patient [35] ; in the remaining cases, the resistant strains were either K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae or carbapenem-resistant K. pneumoniae (CRKP) with unreported resistance mechanisms [32-35, 46, 47] . Decreased sensitivity to ceftazidime-avibactam was reported in one patient with KPC-producing K. pneumoniae [39] .

The largest retrospective cohort study, reported by Tumbarello et al. (2021) , included 577 patients with KPC-producing K. pneumoniae infections, including 391 patients with bacteraemia. In this analysis, there was no difference in 30-day mortality for patients who received ceftazidime-avibactam combination or monotherapy regimens (26% vs. 25%, P = 0.79), and rates of resistance development and adverse events were low (both 3%) [47] .

Another large retrospective cohort study, reported by Jorgensen et al. (2019), included 203 patients who received ceftazidime-avibactam for C 72 h at six US hospitals (2015-2019) and included data for 117 patients with CRE and 63 with P. aeruginosa as well as infections with other Gram-negative and gram-positive pathogens [34] . In the overall cohort, clinical failure, 30-day mortality and 30-day recurrence occurred in 59 (29%), 35 (17%) and 12 (6%) patients, respectively, and outcomes were similar for patients infected with CRE or P. aeruginosa. Of note, ceftazidime-avibactam dosage adjustments for renal function were made for 92 patients but were considered inappropriate for 11 patients (effectively resulting in underdosing); among these patients, five (46%) experienced clinical failure and three (27%) died by day 30. Moreover, only 50 of 74 CRKP isolates underwent baseline testing for ceftazidime-avibactam susceptibility, of which 48 were susceptible [two isolates were ceftazidimeavibactam-resistant, one with New Delhi other than primary or catheter related as independent predictors of mortality, while a combination of at least three antimicrobials was identified as an independent predictor of survival. Thirty-day mortality was 0/1 for a combination regimen of ceftazidime-avibactam ?

colistin ? [32] . Thirty-and 90-day survival rates were 81% and 69%, respectively. Clinical success was 55% overall but differed by infection site (pneumonia, 36%; bacteraemia, 75%; UTI, 88%). Pneumonia (P = 0.045) and receipt of renal replacement therapy [either intermittent haemodialysis or continuous renal replacement therapy (CRRT); P = 0.046] were associated with clinical failure in multivariate analysis. Microbiological failure occurred in 32% of patients and was more common among patients with KPC-3-producing CRE versus KPC-2-producing CRE infections (P = 0.002). Pneumonia was an independent predictor of microbiological failure (P = 0.007). Ceftazidimeavibactam resistance (all in K. pneumoniae harbouring variant KPC-3 enzymes) emerged in eight (10%) patients. Renal replacement therapy was an independent predictor of resistance development (P = 0.009). Importantly, the authors noted that 'optimal dosing of ceftazidime-avibactam in patients with renal insufficiency, particularly those receiving CRRT, is an ongoing challenge for clinicians'. Of note, appropriate ceftazidime-avibactam dosage regimens for patients receiving CRRT have not been established, and there are currently no approved dose recommendations for such patients. Similar rates of resistance emergence were reported in a Spanish study of 47 patients with CRKP infections (Castó n et al. 2020) and in an Italian study (Iannacone et al. 2020) of 23 patients with CRE infections [46] (Table 3) .

In a further US retrospective, multicentre study in 60 severely ill patients with CRE The strain isolated after ceftazidimeavibactam treatment had a mutated blaKPC-2 gene encoding KPC-2 protein with 15 amino acid insertion;

the observed mutation in blaKPC-2 gene has not been described previously He was treated successfully with meropenem for 18 days and subsequently discharged [42] . Most patients received ceftazidime-avibactam as part of a combination regimen following resistance emergence or failure of initial antibiotic treatments; despite relatively severe baseline disease status (median Charlson Comorbidity Index score of 4; 24% of patients admitted to ICU and 59% with sepsis/septic shock), clinical success occurred in 37 patients (90%). Three of the four patients who were clinical failures were undergoing CRRT; all received ceftazidime-avibactam 1.25 g q8h (as noted above, there are no approved ceftazidimeavibactam dosing recommendations for patients on CRRT). No adverse events related to ceftazidime-avibactam treatment occurred, and resistance development was not documented in any patient [42] . Temkin et al. (2017) analysed outcomes for 38 patients in Europe and Australia with infections caused by carbapenem-resistant organisms (36 with CRE and two with P. aeruginosa), 95% of whom received ceftazidime-avibactam as salvage therapy [41] . Clinical and/or microbiological cure occurred in 28 patients (74%). Five patients (21%) with documented microbiological cure died versus ten patients (71%) with no documented microbiological cure (P = 0.01). Rahmati et al. (2017) and Krapp et al. (2017) reported outcomes for 11 and 6 patients, respectively, with KPC-producing K. pneumoniae infections treated with ceftazidime-avibactam in the US [38, 39] . In the cohort of 11 patients, the clinical success rate was 73%, 30-day survival was 82%, 90-day survival was 73%, and in-hospital mortality was 27% [39] . Mortality was 75% among four patients receiving CRRT or haemodialysis (P = 0.02); however, as noted above, approved ceftazidime-avibactam dosing recommendations are not currently available for patients on CRRT (moreover, ceftazidimeavibactam dosages were not reported in this congress abstract). Recurrence occurred in two patients (18%). Decreased sensitivity to ceftazidime-avibactam was noted in one patient (9%), and three patients (27%) had CRE isolated after C 7 days of treatment [39] . In the cohort of six patients, five achieved clinical cure; however, two relapsed with the same KPC-3producing K. pneumoniae strain within 3 weeks of completing ceftazidime-avibactam treatment [38] . One patient with pneumonia experienced clinical failure, despite having a documented ceftazidime-avibactam-susceptible CRKP strain [minimum inhibitory concentration (MIC) = 2 mg/l]. Thus, the overall clinical success rate in this small cohort was 50% [38] .

In two retrospective cohort studies involving MDR or XDR P. aeruginosa infections (in 8 and 10 patients in Spain and the US, respectively) in various locations (including respiratory, blood, bone/joint, skin/wound, and meningitis), clinical success rates with ceftazidime-avibactam treatment were 50-80% [36, 40] . In the Spanish study, 30-and 90-day mortality rates were 13% and 38%, respectively [40] . In-hospital mortality in the US study was 20% [36] . Kuang (Table 3) .

Finally, Katchanov et al. (2018) described a prevalence study of patients infected or colonised with MDR Gram-negative bacteria in a German tertiary care hospital, in which ceftazidime-avibactam was administered to five patients with severe HAP (and bacteraemia in one case) during an outbreak of OXA-48-and CTX-M-14-producing K. pneumoniae [35] . Inhospital mortality occurred in all five patients (100%), and ceftazidime-avibactam resistance emergence on therapy was documented in one patient (three patients were not assessed for resistance emergence), prompting the authors to note that 'novel b-lactam/b-lactamase inhibitor combinations are of limited usefulness in our setting because of the high prevalence of Ambler class B carbapenemases (in Pseudomonas spp. and Escherichia coli but not in Klebsiella spp.) and the emergence of non-susceptibility under therapy'. Of note, the five patients received 2, 57, 86, 8, and 61 days, respectively, of ceftazidime-avibactam therapy, implying a 30-day mortality rate of 2/5 (i.e., 40%) [35] .

Data for 169 patients treated with ceftazidimeavibactam from 17 case series (Table 4) were identified from the literature search [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] . One case series of three patients (Shields et al. 2017 [65] ) was excluded from the literature search results because clinical outcomes for these patients are included in another larger case series published by the same group (Shields et al. 2016 [56] ); data for the latter publication are summarised in Table 4 . Most of the included case series involved CRE/CPE infections (141 patients); 10 publications included data for P. aeruginosa infections (24 patients). Three case series reported emergence of ceftazidime-avibactam resistance on therapy in two of ten patients (20%; one P. aeruginosa; one Citrobacter freundii with KPC detected in initial isolate and undetermined mechanism of ceftazidime-avibactam resistance) [55] ; 3 of 37 patients (8%; all initial isolates were KPC-3-producing K. pneumoniae) [56] and one of two patients (50%) were treated for XDR P. aeruginosa infections [61] .

The literature search identified 26 case reports with data for 26 patients (Table 5 ) treated with ceftazidime-avibactam . As with the other included publications, most of the case reports involved CRE/CPE infections (16 patients, of which 1 was also infected with P. aeruginosa). Emergence of ceftazidime-avibactam resistance on treatment was reported in one patient each in two case reports involving K. pneumoniae bloodstream infections (one KPC-2; one KPC-3) [85, 89] , and an increase in ceftazidime-avibactam MIC was reported for a paediatric patient with cystic fibrosis and acute pulmonary exacerbation caused by B. cepacia complex [81] .

This systematic review provides important insights into the real-world use of ceftazidimeavibactam treatment for adults with serious Gram-negative infections with limited treatment options. Although limited by potential publication bias (the tendency for positive results to be more likely to be published than negative results) and the qualitative approach necessitated by the inclusion of heterogenous data representing multiple patient populations, infection types, and bacterial pathogens, the included data are consistent with the broad definition of 'limited treatment options' in the European Summary of Product Characteristics for ceftazidime-avibactam [14] and generally reflect the expected usage of ceftazidime-avibactam in this setting.

As expected, most of the included publications involved severely ill patients with significant comorbidities; the main pathogens were CRE/CPE and P. aeruginosa. A large proportion of reported cases treated with ceftazidime-avibactam included either primary or secondary bacteraemia, and many involved combination treatment with other antibiotics. The relatively wide inclusion criteria for literature in the current analysis [notable exclusions were paediatric data and studies involving pathogens listed in the European Summary of Product Characteristics as non-susceptible to ceftazidime-avibactam (e.g., Acinetobacter spp. or MBL-producing isolates)] and the resulting large number of publications encompassing multiple patient populations, infection types, and various endpoints and definitions limit the possibility for quantitative analysis and warrant caution in generalising the findings. However, an advantage of this broad scope is the inevitable inclusion of several publications that have been subject to more formal analysis. Onorato et al.

(2019) reported a meta-analysis of 11 studies including 396 patients with CRE or carbapenem-resistant P. aeruginosa infections treated with ceftazidime-avibactam [92] ; these 11 studies were all included in the current review. The meta-analysis by Onorato et al. was designed to assess the impact of ceftazidimeavibactam monotherapy versus combination therapy with other antibiotics. Rates of mortality [38% for combination therapy and 31% for monotherapy; risk ratio (RR) 1.18, 95% CI 0.88-1.58; P = 0.259] and microbiological cure (65% vs. 63%, respectively; RR 1.04, 95% CI 0.85-1.28, P = 0.705) were comparable for ceftazidime-avibactam as monotherapy or as part of a combination regimen [92] . A similar network meta-analysis by Fiore et al. (2020) [93] included six observational studies, all of which are also included in the current review [18, 20, 23, 28, 30, 37] . Similarly, Dietl et al. (2020) reviewed 11 observational and comparative studies of ceftazidime-avibactam in patients with CPE infections (including 8 in patients with KPC-and 3 in patients with OXA-48-producing Enterobacterales) [94] , all of which were also included in the current review [18, 19, 23, 28, 30, 31, 34, 38, 41, 49, 56] . Finally, a systematic review of severe infectious complications among patients with haematological malignancies identified three studies of ceftazidime-avibactam [95] , of which two were included in the current review (the third was excluded as it involved treatment of an infection caused by an MBL-producing organism) [23, 53] .

The current qualitative analysis is an attempt to complement, rather than replicate, the metaanalyses and RCTs that were excluded from our dataset [92] [93] [94] [95] [96] [97] [98] [99] [100] . Although lacking the statistical robustness of RCTs or meta-analyses, advantages of our qualitative approach include the broad inclusion criteria and focus on observational data, in contrast to the relatively selective inclusion criteria inherent in metaanalyses and RCTs. Given these broad inclusion criteria, our dataset inevitably included a varied and heterogeneous patient population and a mixture of different assessments and outcome measures; as such, we are unable to provide overall or aggregated efficacy data for ceftazidime-avibactam across the different publications that we included. Nevertheless, this review provides important insights into how ceftazidime-avibactam is being used in practice for the treatment of serious Gramnegative infections with limited treatment options, in particular, those caused by non-MBL-producing CRE and P. aeruginosa. In some cases, positive clinical outcomes were reported with documented reductions in renal toxicity compared with other possible treatment options (e.g., aminoglycosides and/or colistin/ polymixins). The accumulating data from RCTs and real-world clinical experience with ceftazidime-avibactam have prompted its inclusion in various national and regional guidance documents and management protocols [101] [102] [103] [104] [105] [106] [107] . For example, guidance by the Infectious Diseases Society of America for the management antimicrobial-resistant Gram-negative infections recommends ceftazidime-avibactam as a preferred treatment option for CRE and P. aeruginosa infections both within and outside of the urinary tract [107] .

The review also highlights areas in which further research may help elucidate optimal use of ceftazidime-avibactam (for example, in patients undergoing CRRT). In addition, and not unexpectedly given the nature of the limited treatment options setting (including complicated infections and extensive and complex comorbidities), the analysis included several publications reporting resistance emergence and/or reduced susceptibility during therapy with ceftazidime-avibactam [29, 32-35, 39, 47, 55, 56, 61, 85, 89] . A further study specifically evaluated outcomes for five patients with documented resistance ceftazidime-avibactam emergence [60] . Of note, information on the timing of resistance emergence relative to initiation of ceftazidime-avibactam therapy was reported inconsistently. As with all antimicrobial agents, use of ceftazidime-avibactam should be guided, wherever possible, by pathogen culture/phenotypic susceptibility results (ideally supported by genotypic detection and characterisation of any carbapenemases identified) and local resistance patterns. In cases where patients show signs of deterioration or failure to improve, it is important that purposeful microbiological sampling is undertaken to enable early detection of potential resistance development on therapy.

An important point to highlight regarding the inclusion criteria and data extraction is that although we endeavoured to exclude publications reporting off-label use of ceftazidime-avibactam, in some instances, we did include publications reporting data on the use of ceftazidime-avibactam outside of the approved European Summary of Product Characteristics. For example, some reported studies included patients undergoing CRRT [32, 42, 48, 50, 55] , although there are no approved ceftazidimeavibactam dosing recommendations for such patients; similarly, some studies reported the use of doses of ceftazidime-avibactam (including adjustments for renal function) outside of the dosing recommendations in the European Summary of Product Characteristics. One case series reported on the use of ceftazidime-avibactam in surgical prophylaxis in two patients with cystic fibrosis undergoing lung transplantation [52] (this publication was nonetheless included because both patients also subsequently received ceftazidime-avibactam postoperatively for infections consistent with the 'limited treatment options' definition). Moreover, a few studies reported on the use of ceftazidime-avibactam in combination with other agents to treat infections caused by MBL-producing bacteria or species listed in the European Summary of Product Characteristics as inherently resistant to ceftazidime-avibactam (for example Acinetobacter species); we excluded such publications, except in a few instances where the data were reported alongside/within a larger patient group in which the reported use of ceftazidime-avibactam was otherwise consistent with approved labelling. A case series of three patients with XDR P. aeruginosa infections reported use of an off-label dose of ceftazidimeavibactam alongside aztreonam [61] ; we nevertheless included these data since a second patient in the series received standard-dose ceftazidime-avibactam (plus colistin then aztreonam) and was reported to have on-therapy resistance emergence after 60 days of treatment.

Although it has been anecdotally reported that the standard ceftazidime-avibactam dosage regimen for patients with CrCL C 50 ml/min (i.e., 2.5 g by 2-h intravenous infusions q8h) may be suitable for patients with pneumonia undergoing continuous venovenous haemodiafiltration [108, 109] , it is important to note that appropriate ceftazidime-avibactam dosage regimens for patients receiving CRRT have not been established. In the retrospective study of 77 patients with CRE infections by Shields et al. (2018) , 3 patients required CRRT, including 2 of the 5 patients with pneumonia [32] . Ceftazidime-avibactam doses for these three patients ranged from 0.94 g every 12 h (q12h) to 2.5 g q8h. The link between ceftazidime-avibactam underdosing and clinical failure in renal impairment was identified in the phase 3 RECLAIM trial [5] and has been further reviewed by Li et al. (2020) [110] . Considering the small sample size and variable ceftazidime-avibactam dosing in the CRRT subset in the analysis by Shields et al. [32] , the reported statistical association between pneumonia and treatment failure should be interpreted with caution.

In conclusion, the data reviewed here demonstrate qualitative evidence of successful use of ceftazidime-avibactam for treatment of hospitalised patients with Gram-negative infections with limited treatment options, based on clinical and microbiological cure outcomes and mortality, including evidence of effectiveness against CRE and MDR P. aeruginosa. The review also highlights areas where further data are needed, for example, on the use of ceftazidime-avibactam in patients undergoing CRRT. from Eumedica (2016-2018). Margaret Tawadrous and Paurus Irani are employees of and shareholders in Pfizer.

Compliance with Ethics Guideline. This article is based on published literature and does not contain any previously unreported studies with human participants or animals.

Data Availability. This article is based on published literature.

Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc/4.0/.

Global antimicrobial resistance in gram-negative pathogens and clinical need

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of gram-negative bacterial infections

Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections

Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program

ceftazidimeavibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intraabdominal infections in hospitalised adults in Asia

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intraabdominal infections in hospitalized adults: results of a randomized, double-blind. Phase II trial

Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme

AVYCAZ (ceftazidime and avibactam) for injection, for intravenous use

Summary of Product Characteristics: Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion

Committee for Medicinal Products for Human Use (CHMP)

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae

Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae

Efficacy of ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae

Clinical outcomes associated with various treatment options for infections caused by carbapenem-resistant enterobacteriaceae

Improved Outcomes for Cancer Patients Treated With ceftazidime-avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia. Open Forum Infectious Diseases

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients

2262. ceftazidime-avibactam vs. Polymyxin B in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases

Ceftazidime/ avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study

Factors Associated with Mortality in Carbapenem-Resistant Enterobacteriaceae Bacteremia: Focus on Antibiotic Therapy. Open Forum Infectious Diseases

Bloodstream infections due to carbapenem-resistant klebsiella pneumoniae: a single-center retrospective study on risk factors and therapy options

Ceftazidimeavibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

Does ceftazidime-avibactam (CAZ-AVI) Improve Short-and Long-Term Outcomes Among Solid-Organ Transplant (SOT) Recipients with Carbapenem-Resistant Enterobacteriaceae (CRE) Infections? Open Forum Infectious Diseases

Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae

ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients

Pneumonia and renal replacement therapy are risk factors for ceftazidimeavibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections

Ceftazidimeavibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections

Carbapenemresistant Gram-negative pathogens in a German university medical center: prevalence, clinical implications and the role of novel beta-lactam/betalactamase inhibitor combinations

Outcomes with Ceftazidime/Avibactam in patients with carbapenem-resistant pseudomonas infections: a multi-center study. Open Forum Infectious Diseases

Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections

Treating complicated carbapenem-resistant Enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam. Open Forum Infectious Diseases

Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa

Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms

Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant Enterobacterales

Mortality of pandrug-resistant klebsiella pneumoniae bloodstream infections in critically Ill patients: a retrospective cohort of 115 episodes

Clinical characteristics and outcomes of patients with multidrugresistant Gram-negative bacterial infections treated with ceftazidime/avibactam

Experience of Ceftazidime/avibactam in a UK tertiary cardiopulmonary specialist center

Ceftazidime-avibactam susceptible to resistant KPC-producing Enterobacterales bloodstream infections: an observational study

Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study

Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia

Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam

Compassionate use ceftazidime/avibactam (Cazavi) for carbapenem-resistant (Cr) Gram-negative rod (Gnr) infections

ceftazidime-avibactam as salvage therapy for infections caused by Enterobacteriales coresistant to carbapenems and polymyxins

Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam

ceftazidime-avibactam for Gram-negative multidrugresistant bacteria in hematological patients: a single-center experience

Ceftazidime-avibactam as empiric therapy in febrile neutropenic high-risk haematological patients, HMpts, colonized with carbapenem-resistant Klebsiella pneumoniae (CRKP). 28th European Congress of Clinical Microbioogy and Infectious Diseses (ECCMID)

Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae

Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections

Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series

ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia

Clinical experience with ceftazidime/ avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa

Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series

Ceftazidime/ avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature. Infection

Allograft hemorrhage as a manifestation of carbapenem-resistant Klebsiella pneumonia infection in kidney transplant recipients: Case series. Medicine (Baltimore)

Use of ceftazidime-avibactam and ceftolozane-tazobactam after lung transplantation

Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli

Emergence of ceftazidime-avibactam resistance due to plasmidborne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections

Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam

Successful treatment of Klebsiella pneumoniae harboring a Klebsiella pneumoniae carbapenemase isolated from lumbar wound infection and blood in a patient with hardware retention. Case Rep Infect Dis

Successful treatment of carbapenemase-producing pandrugresistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother

A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy

Treatment of a Klebsiella pneumoniae KPC cellulitis and gut decolonization with ceftazidime/ avibactam in a migrant from Libya

ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation

Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis

Ceftazidime/avibactam for refractory bacteremia, vertebral diskitis/osteomyelitis with pre-vertebral abscess and bilateral psoas pyomyositis secondary to Klebsiella Pneumoniae carbapenemase-producing bacteria (KPC)

Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin

Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: A case report

Rocha-Pereira N. Carbapenemase-producing Klebsiella pneumoniae intra-abdominal infection successfully treated with ceftazidime/avibactam plus tigecycline

Carbapenemase-producing Raoultella planticola: A rare cause of pneumonia and bacteremia. Diseases

Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report

A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam

Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient

ceftazidime-avibactam for the treatment of multidrug resistant Burkholderia cepacia complex in a pediatric cystic fibrosis patient

Managing all the genotypic knowledge: approach to a septic patient colonized by different Enterobacteriales with unique carbapenemases

Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report

Ceftazidime/avibactam neurotoxicity in an adult patient with normal renal function

Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment

Lumbar arthrodesis infection by multi-resistant Klebsiella pneumoniae, successfully treated with implant retention and ceftazidime/avibactam

Ceftazidime-Avibactam for the treatment of post-neurosurgical meningitis caused by a Klebsiella pneumoniae carbapenemase (KPC)-Producing Klebsiella pneumoniae. Open Forum Infectious Diseases

Prosthetic joint infection from carbapenemase-resistant Klebsiella pneumoniae successfully treated with ceftazidime-avibactam

Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: a case report and review of literature

Successful treatment of early post-transplant bloodstream and pulmonary infection caused by carbapenem-resistant klebsiella pneumoniae with a combination of ceftazidimeavibactam and carbapenem: a case report

Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam

Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis

Ceftazidimeavibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network metaanalysis

Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales

Ceftazidime/avibactam and ceftolozane/tazobactam for multidrug-resistant gram negatives in patients with hematological malignancies: current experiences

Ceftazidime/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: a metaanalysis of randomised controlled trials

Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis

Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis

Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis

Is ceftazidime/avibactam an option for serious infections due to extended-spectrum-betalactamase-and AmpC-producing enterobacterales?: a Systematic Review and Meta-analysis

Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the

National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing

The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for Infect Dis Ther management of intra-abdominal infections

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party

Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections

Steady-state ceftazidime-avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for Pseudomonas aeruginosa pneumonia and undergoing continuous venovenous hemodiafiltration

Population pharmacokinetics of ceftazidime-avibactam among critically-ill patients with and without receipt of continuous renal replacement therapy. Open Forum Infectious Diseases

Considerations in the selection of renal dosage adjustments for patients with serious infections and lessons learned from the development of ceftazidime-avibactam

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Funding. The journal's Rapid Service Fee was funded by Pfizer. No payments or honoraria were made to the authors in respect of manuscript preparation. All authors provided input at each stage of manuscript development and approved the final version for submission.Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this Infect Dis Ther article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.Medical Writing Assistance. Medical writing support was provided by Mark Waterlow, BSc, CMPP, of Prime Medica Ltd, Knutsford, Cheshire, UK, and was funded by Pfizer.